Krystle Karoscik Krystle Karoscik

Krystle Karoscik is a Oncology Clinical Research Strategist at Translational Drug Development (TD2) and serial entrepreneur, with 10 years of program development and healthcare consulting experience in oncology clinical trials. Krystle serves as an ambassador for the Center for Advancing Innovation (CAI), and has developed commercialization strategies for novel therapeutics resulting in the launch of early-stage startups. She is the co-founder of GlioLink Inc., pursuing innovative monoclonal antibodies for glioblastoma research. She is also the co-founder and managing partner of Onciva Management, focused on consultative services and capital investments.

COVID-19’s Long-Lasting Impact on Clinical Trials

With COVID-19 impacting the conduct of clinical trials, a lot of discussion has been ...